TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04221854

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool-based SDC2 DNA methylation test
Description: Stool-based SDC2 DNA methylation test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fecal immunochemical test
Description: Fecal immunochemical test
Study: NCT02019225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis session of at least 4.25 hours
Description: Facilities randomized to the Intervention arm will adopt the practice of recommending dialysis session durations of at least 4.25 hours for all patients initiating hemodialysis treatment regardless of body size or dialysis solute clearance measurements.
Study: NCT01116141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH-4051
Description: Different doses CH-4051 to be compared

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH-4051
Description: Different doses CH-4051 to be compared

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH-4051
Description: Different doses CH-4051 to be compared

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH-4051
Description: Different doses CH-4051 to be compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: 20 mg MTX weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 1 mg folic acid daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: 1 mg folic acid daily
Study: NCT01930149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed patient outreach intervention
Description: This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
Study: NCT03217942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGF
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGF
Description: Intramuscular injection
Study: NCT03707613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DWT learning curve
Description: trainees learn to perform DWT after unsuccessful initial cannulation
Study: NCT00307333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeRO heart rate characteristics monitor
Description: 24 hour continuous HRC monitoring with display
Study: NCT03621527

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anesthesia combined with intravenous analgesia by remifentanil
Description: intravenous analgesia by remifentanil is provided and adapted to the patients' needs during the whole procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluoroscopy-guided epidural anesthesia
Description: Identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure
Study: NCT02654249

Intervention type: DEVICE
Group type: OTHER
Intervention: Transanal hemorrhoidal dearterialization + mucopexy (THD).
Description: Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure™ hemorrhoidectomy
Description: Excisional hemorroidectomy performed with Ligasure™

Intervention type: DEVICE
Group type: OTHER
Intervention: THD anoscope and doppler
Description: An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure Vessel Sealing
Description: A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
Study: NCT02790255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water
Study: NCT01979224

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Educational intervention for parents
Description: educational sessions once a week two hours for a month and later educational reinforcement and monitoring asthma control monthly for nine months
Study: NCT00714467

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expert System Only
Description: expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Assisted
Description: The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
Study: NCT01770613

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Stem cells
Description: Allogeneic mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: Allogeneic mesenchymal stem cells
Study: NCT04458272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1001b
Description: 250 mg, twice daily, continuous oral administration
Study: NCT05646212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project ECHO
Description: Project Extension for Community Healthcare Outcomes® (ECHO): This EBP, tested originally to facilitate HCV care into non-specialty settings, is based on established educational theories of social learning \& behavior change in where non-specialists collaborate with specialists, resulting in an innovative healthcare delivery model that results in equivalent quality care for patients in non-specialty settings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project ECHO
Description: Project Extension for Community Healthcare Outcomes® (ECHO): This EBP, tested originally to facilitate HCV care into non-specialty settings, is based on established educational theories of social learning \& behavior change in where non-specialists collaborate with specialists, resulting in an innovative healthcare delivery model that results in equivalent quality care for patients in non-specialty settings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Payment for Performance
Description: P4P in healthcare, endorsed by 3 IOM reports, gives financial incentives to clinicians for adhering to clinical guidelines and achieving better health outcomes. One 2007 IOM report recommended physician incentives so that profitability and improved healthcare delivery is aligned with patient safety goals and strengthen the business case for healthcare quality and safety.
Study: NCT00376337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic antifungal therapy
Description: IV
Study: NCT02485457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volume loading
Description: Volume loading with Ringer Lactate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volume loading
Description: Volume loading with Ringer Lactate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer solution
Study: NCT00533026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT03244748

Intervention type: PROCEDURE
Intervention: Ventricular tachycardia ablation
Description: Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously

Intervention type: PROCEDURE
Intervention: Ventricular tachycardia ablation
Description: Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
Study: NCT03812484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCF Supervision
Description: SCF Supervision entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). SCF Supervision includes regular random drug testing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parole-as-Usual
Description: Parolees are supervised under standard parole supervision practice in New Jersey
Study: NCT01105091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT-385781A (Actelion Epoprostenol)
Description: per Prescribing Information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flolan®
Description: Per Prescribing Information
Study: NCT00916149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Description: The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study.
Study: NCT01978535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron infusion
Description: 5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
Study: NCT03590015

Intervention type: OTHER
Group type: OTHER
Intervention: Old invitation letter
Description: Invitation Letter written by researchers/doctors

Intervention type: OTHER
Group type: OTHER
Intervention: New invitation Letter
Description: Invitation Letter written in simple sentences and a sequential structure of basic information in the rewritten information Letter
Study: NCT00161486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel 100 mg daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyline
Description: Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acyline
Description: Placebo acyline injections every two weeks (2 doses)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Testosterone gel
Description: placebo testosterone gel daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Testosterone gel
Description: placebo testosterone gel daily for 4 weeks
Study: NCT00745407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Study: NCT01758458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Beta
Description: Given intralesionally
Study: NCT01935206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg/kg)
Study: NCT01754857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT00544648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: (AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
Study: NCT02939989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Coformulated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Coformulated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet for oral administration
Study: NCT01965977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3mg/m2, on day 1 and 15 SC Repeat every month for 12months
Study: NCT04874181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silverfit 3D
Description: Virtual reality game used for rehabilitation of stroke patients
Study: NCT04509141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture points used were EXHN5 Taiyang, GB20 Fengchi, TE5 Waigun, GB41 Zulinqi

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture points used were EXHN5 Taiyang, GB20 Fengchi, TE5 Waigun, GB41 Zulinqi
Study: NCT02123316

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pangramin Plus D. pteronyssinus
Description: Subcutaneous immunotherapy with Dermatophagoides pteronyssinus

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for subcutaneous injection
Study: NCT04561596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OnComfort autohypnosis
Description: Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual except for the virtual reality mask and autohypnosis software that will run during the whole intervention.~Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual, without the OnComfort autohypnosis system
Description: The Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual. Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention.
Study: NCT01345396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education about asthma
Description: Three face-to-face appointments (\<20, 36 weeks of gestation and 12 weeks after the baby birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
Study: NCT01935206

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03559374

Intervention type: OTHER
Intervention: Vanadis NIPT system
Description: A novel cost effective not NGS (next-generation sequencing) test, based on imaging single DNA molecules for high precision NIPT (non-invasive prenatal testing)
Study: NCT00594321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPACE CpsXL Bone Cement and SPACE 360 Delivery System
Description: SPACE CpsXL Bone Cement and SPACE 360 Delivery System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard vertebroplasty
Description: standard vertebroplasty
Study: NCT03216811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nutraceutical
Description: 8-week administration of nutraceutical compound
Study: NCT04267718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of Padua and IMPROVE Bleeding scores
Description: Eligible patients hospitalized in centres randomized to the Experimental group will be evaluated, within 48 hours from admission to hospital, by means of the Padua predictive score and the IMPROVE Bleeding score.
Study: NCT00074581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine
Description: 400 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine
Description: 400 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 300 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 300 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage depends on weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage depends on weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine/Lamivudine
Description: 150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine/Lamivudine
Description: 150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
Study: NCT01372722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS Activa PC systems Medtronic
Description: 130Hz, 90us pulsewidth, 4V Amplitude

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS, Activa PC systems Medtronic
Description: 30Hz, 90us pulsewidth, 4V Amplitude
Study: NCT01491295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine plus adefovir
Description: Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
Study: NCT00351416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 20 mg orally one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 20 mg orally one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAL-GLU GnRH antagonist
Description: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAL-GLU GnRH antagonist
Description: 5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously